Kachrimanidou Melina, Tsintarakis Eleftherios
First Department of Microbiology, Aristotle University of Thessaloniki, Medical School, 54124 Thessaloniki, Greece.
Microorganisms. 2020 Jan 31;8(2):200. doi: 10.3390/microorganisms8020200.
infection (CDI) has emerged as a major health problem worldwide. A major risk factor for disease development is prior antibiotic use, which disrupts the normal gut microbiota by altering its composition and the gut's metabolic functions, leading to the loss of colonization resistance and subsequent CDI. Data from human studies have shown that the presence of , either as a colonizer or as a pathogen, is associated with a decreased level of gut microbiota diversity. The investigation of the gut's microbial communities, in both healthy subjects and patients with CDI, elucidate the role of microbiota and improve the current biotherapeutics for patients with CDI. Fecal microbiota transplantation has a major role in managing CDI, aiming at re-establishing colonization resistance in the host gastrointestinal tract by replenishing the gut microbiota. New techniques, such as post-genomics, proteomics and metabolomics analyses, can possibly determine in the future the way in which C. difficile eradicates colonization resistance, paving the way for the development of new, more successful treatments and prevention. The aim of the present review is to present recent data concerning the human gut microbiota with a focus on its important role in health and disease.
艰难梭菌感染(CDI)已成为全球主要的健康问题。疾病发展的一个主要风险因素是先前使用过抗生素,这会通过改变肠道微生物群的组成和肠道代谢功能来破坏正常的肠道微生物群,导致定植抗性丧失并随后引发CDI。来自人体研究的数据表明,无论作为定植菌还是病原体,其存在都与肠道微生物群多样性水平降低有关。对健康受试者和CDI患者的肠道微生物群落进行调查,有助于阐明微生物群的作用,并改善目前针对CDI患者的生物治疗方法。粪便微生物群移植在管理CDI方面发挥着重要作用,旨在通过补充肠道微生物群来重新建立宿主胃肠道的定植抗性。诸如后基因组学、蛋白质组学和代谢组学分析等新技术,未来可能会确定艰难梭菌消除定植抗性的方式,为开发新的、更成功的治疗方法和预防措施铺平道路。本综述的目的是介绍有关人类肠道微生物群的最新数据,重点关注其在健康和疾病中的重要作用。